Recent Analysts’ Ratings Changes for IQVIA (IQV)

A number of research firms have changed their ratings and price targets for IQVIA (NYSE: IQV):

• 6/27/2026 – IQVIA was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/17/2026 – IQVIA had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $200.00 price target on the stock, down from $225.00.
• 6/17/2026 – IQVIA had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $200.00 price target on the stock, down from $225.00.
• 6/14/2026 – IQVIA was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/6/2026 – IQVIA was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/3/2026 – IQVIA was given a new $210.00 price target by HSBC Holdings plc.
• 5/7/2026 – IQVIA was given a new $225.00 price target by Morgan Stanley.
• 5/4/2026 – IQVIA was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.